Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT06037265
Other study ID # PR-0164
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date January 20, 2022
Est. completion date November 2023

Study information

Verified date September 2023
Source PAVmed Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The PortIO is intended to provide non-emergent vascular access in chronic kidney disease (CKD) patients where preservation of venous anatomy is desired and iatrogenic damage to the veins should be avoided and/or patients with poor/difficult vascular access. The PortIO device may be inserted into the proximal or distal tibia or the proximal humerus in adults, and provides up to 60 days of intraosseous vascular access for delivery of fluids and medications.


Description:

This is a prospective, open label, single arm, non-randomized, multicentric first in human clinical trial of the PortIO device for intraosseous infusion of fluids and/or medications for up to 60 days in subjects that meet the inclusion criteria. Both hospitalized patients as well as outpatients can be screened and, if appropriate, can be consented and enrolled into the study. They will have the PortIO device implanted by a qualified physician and then undergo prescribed infusions as needed and determined by the treating physician over either a 7-day or a 60-day period. The device will then be removed after the 7 days or 60 days of use and the subject followed up at 30 days after explant.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 40
Est. completion date November 2023
Est. primary completion date November 2023
Accepts healthy volunteers No
Gender All
Age group 22 Years to 99 Years
Eligibility Inclusion Criteria: - Subjects must meet the following criteria are eligible for participation in the study: 1. Subject is > 22 years old 2. Subject has grade 3 or higher CKD and is receiving or may receive renal replacement therapy with hemodialysis OR has poor/difficult vascular access. 3. Subject does NOT need urgent or emergent vascular access; 4. Subject, or authorized representative, signs a written Informed Consent form to participate in the study, prior to any study mandated procedures 5. Subject is willing and able to complete follow-up requirement Exclusion Criteria: - Subjects must be EXCLUDED from participation in this study if ANY of the following criteria are met: 1. Fracture (within 6 months), bone tumor, or structural bone abnormality (such as osteogenesis imperfect, avascular necrosis, and severe osteoporosis) of the target bone 2. Excessive overlying soft tissue, nerves, arteries, tendons or absence of anatomic landmarks at the target site 3. Previous orthopedic procedure at or near the insertion site (e.g. artificial joint, rigid fixation hardware) 4. IO access or attempted IO access in the target bone within 7 days 5. Known or suspected allergy to any device component or materials contained in the device 6. Local tissue factors preventing proper device stabilization and / or access including local infection, fragile tissue and absence of adequate or excessive overlying soft tissue. 7. Subject with known unstable cardiac disease (recent MI within 30 days, cardiac surgery within 6 months, unstable angina, severe aortic stenosis/regurgitation, severe congestive heart failure, severe mitral stenosis/regurgitation), uncontrolled diabetes (blood glucose >240 mg/dl) or subjects on immunosuppressive medications (e.g. organ transplant patients) 8. Subjects who are anticipated to receive infusion of blood or blood products, chemotherapeutic agents, hypertonic solutions, caustic agents or any agents known to harm bone marrow or cause bone marrow suppression such as azathioprine, procainamide, sulfasalazine via the test device. 9. Insertion into the humerus on the same side as a previous mastectomy 10. Known allergy to contrast media or local anesthetics (e.g. lidocaine, bupivacaine) 11. Subjects with known bleeding disorders including thrombocytopenia, thrombasthenia, hemophilia or Von Willebrand's disease. 12. Subjects with a history of hypercoagulable disorders such as protein S or C deficiency, Factor 5 Leiden resistance, Antithrombin III deficiency, Antiphospholipid antibody syndrome, Heparin Induced Thrombocytopenia etc. 13. Subjects who are anticipated to need power injections via the test device for CT scan or angiography 14. Subject has other medical, social or psychological problem that in the opinion of the investigator precludes them from fully participating 15. Women who are pregnant, women who are attempting to become pregnant, as well as women who are breast feeding.

Study Design


Intervention

Device:
PAVmed PortIOâ„¢ Intraosseous Infusion System
The PortIO is intended to provide non-emergent vascular access in chronic kidney disease (CKD) patients where preservation of venous anatomy is desired and iatrogenic damage to the veins should be avoided and/or patients with poor/difficult vascular access. The PortIO device may be inserted into the proximal or distal tibia or the proximal humerus in adults, and provides up to 60 days of intraosseous vascular access for delivery of fluids and medications.

Locations

Country Name City State
Colombia Cediul Barranquilla Atlantico
Colombia Sabbag Radiologos Barranquilla Atlantico
Colombia Cirulaser Andes Bogotá Bogota
Colombia Centro Medico Imbanaco Cali Valle De Cauca

Sponsors (1)

Lead Sponsor Collaborator
PAVmed Inc.

Country where clinical trial is conducted

Colombia, 

Outcome

Type Measure Description Time frame Safety issue
Primary Primary Performance Incidence of successful implant in the target anatomic location; Patency through the implant duration, with final patency assessment performed immediately prior to device explant; Incidence of successful device explant Entire duration of Study an average of 2 years
Primary Primary Safety Incidence of serious device-related adverse events Entire duration of Study and average of 2 years
Secondary Secondary Endpoint Incidence of all device-related adverse events, whether serious or non-serious Entire duration of Study an average of 2 years
See also
  Status Clinical Trial Phase
Terminated NCT03539861 - Immunomodulatory Biomimetic Device to Treat Myocardial Stunning in End-stage Renal Disease Patients N/A
Recruiting NCT03311321 - Vitamin K to Slow Progression of Cardiovascular Disease Risk in Hemodialysis Patients N/A
Completed NCT05630729 - Living With CKD: An E-Learning Platform for Adolescents With CKD About the Disease and Its Management N/A
Withdrawn NCT03998917 - Pathophysiological Characterization of the Neuromuscular Function of a Population With Multiple Comorbidities Suffering From Chronic Renal Failure in Pre-dialysis.
Recruiting NCT05489120 - Low-Protein Diet With Low-Protein Foods Versus a LPD Without LP Foods in Patients With Chronic Kidney Disease (CKD) N/A
Completed NCT04207203 - Healthy Diet Rich in Potassium to Chronic Kidney Disease With Sodium Zirconium Cyclosilicate: A Feasibility Study N/A
Recruiting NCT01591876 - Exercise and Vascular Function in Haemodialysis Patients Phase 2
Not yet recruiting NCT04608422 - Bioeletric Stimulation in Patients With Chronic Kidney Failure N/A
Completed NCT03868371 - Acute Changes in the Mineral Metabolism After a High Phosphorous Containing Meal in Dialysis Patients N/A
Active, not recruiting NCT05225454 - The Life Style Patterns and the Development Trend of Chronic Diseases in Healthy and Sub-healthy Groups Were Analyzed by Using Data-mining Techniques
Completed NCT03459807 - Blood Pressure Lowering in Dialysis (BOLD) Trial Phase 2
Not yet recruiting NCT03005847 - The Effect of Fermented Papaya Preparation on Patients With Chronic Kidney Disease Under Dialysis Receiving Intravenous Iron N/A
Recruiting NCT05726526 - CKD Specific Telemonitoring Platform to Minimize Adverse Outcomes in High Risk CKD Patients N/A
Recruiting NCT04330807 - Physiopathology of Neuromuscular Function Related to Fatigue in Chronic Renal Disease N/A
Active, not recruiting NCT02858778 - Timing of Acute Palliative Care Consultation in Critically Ill Patients N/A
Active, not recruiting NCT04034966 - Utility of Telemedicine in the Follow-Up of Patients in Peritoneal Dialysis N/A
Completed NCT04012957 - Desidustat in the Treatment of Anemia in CKD Phase 3
Terminated NCT02039167 - Left Atrial Appendage Occlusion vs. Usual Care in Patients With Atrial Fibrillation and Severe Chronic Kidney Disease N/A
Completed NCT01764854 - Pharmacodynamic Study of AZD1722 in End-stage Renal Disease Patients on Hemodialysis Phase 2
Active, not recruiting NCT05350098 - Efficacy of Plant-protein Diets in Patients With Chronic Kidney Disease N/A